Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Vaccination Response Following Administration of Ixekizumab to Healthy Subjects

NCT02543918 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02543918
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02543918 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Vaccination Response Following Administration of Ixekizumab to Healthy Subjects
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2015
Completion date
December 31, 2015
Enrollment
84 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

healthy